Incyte EV/EBIT INCY

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2013.

Today, Oct 23, 2026: 10.1×
10-year median: 24.2×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 9.8× to 494×
Peer median: 24.0×

Incyte's EV/EBIT is 10.1× as of Oct 23, 2026.

That is below its ten-year median of 24.2×, lower than on 99% of days in the last ten years.

Over that time it ranged from 9.8× in Oct 2026 to 494× in Aug 2024.

The median for 10 biotech stocks of a similar size is 24.0×.

EV/EBIT over time

median 24.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.1×	9.8×	14.9×
2025	13.5×	12.5×	205×
2024	486×	11.7×	494×
2023	21.0×	16.4×	26.7×
2022	24.1×	16.9×	27.5×
2021	21.9×	18.8×	36.2×
2020	47.3×	31.0×	50.7×
2019	44.0×	41.3×	283×
2018	n/m a value too high to mean anything
2017	162×	121×	195×
2016	112×	97.8×	288×
2015	n/m a value too high to mean anything
2014	342×	273×	347×
2013	261×	85.0×	270×

Against its peers

Companies in Biotechnology nearest Incyte's size, closest first, today.

Company	EV/EBIT
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
ALNYAlnylam Pharmaceuticals	27.9×
EXELExelixis	15.4×
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
ONCBeOne Medicines	42.2×
TECHBIO-TECHNE	44.9×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
REGNRegeneron Pharmaceuticals	20.0×
Peer median	24.0×

Where Incyte ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Incyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.